Skip to content
lifestyle.phenomena.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Marvel Biosciences Corp.
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
August 5, 2026
New Autism Research to be Presented at European Purine Scientific Meeting
June 26, 2026
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
April 23, 2026
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
April 16, 2026
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
April 7, 2026
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
March 30, 2026
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
March 25, 2026